Oppenheimer & CO Inc Adma Biologics, Inc. Transaction History

Oppenheimer & CO Inc

$6.42 Billion
Q3 2024

A detailed history of Oppenheimer & CO Inc transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 94,938 shares of ADMA stock, worth $1.77 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

94,938

Previous 51,102 85.78%

Holding current value

$1.77 Million

Previous $571,000 232.22%

% of portfolio

0.03%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$11.21 - $20.03 $491,401 - $878,035	43,836 Added 85.78%	94,938 $1.9 Million
Q2 2024 Aug 07, 2024	SELL	$5.98 - $11.18 $257,785 - $481,947	-43,108 Reduced 45.76%	51,102 $571,000
Q1 2024 May 06, 2024	SELL	$4.4 - $6.74 $121,994 - $186,873	-27,726 Reduced 22.74%	94,210 $621,000
Q4 2023 Feb 13, 2024	BUY	$3.08 - $4.52 $14,787 - $21,700	4,801 Added 4.1%	121,936 $551,000
Q3 2023 Nov 07, 2023	SELL	$3.47 - $4.61 $7,824 - $10,395	-2,255 Reduced 1.89%	117,135 $419,000
Q2 2023 Aug 02, 2023	SELL	$3.12 - $4.22 $20,280 - $27,430	-6,500 Reduced 5.16%	119,390 $440,000
Q1 2023 May 10, 2023	BUY	$3.01 - $3.87 $9,225 - $11,861	3,065 Added 2.5%	125,890 $416,000
Q4 2022 Feb 07, 2023	SELL	$2.47 - $3.88 $191,425 - $300,700	-77,500 Reduced 38.69%	122,825 $476,000
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $62,733 - $88,382	30,903 Added 18.24%	200,325 $487,000
Q2 2022 Aug 08, 2022	BUY	$1.43 - $2.2 $242,273 - $372,728	169,422 New	169,422 $335,000
Q2 2020 Aug 11, 2020	SELL	$2.42 - $3.29 $26,223 - $35,650	-10,836 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$1.5 - $4.59 $1,215 - $3,717	810 Added 8.08%	10,836 $31,000
Q4 2019 Feb 07, 2020	BUY	$3.89 - $5.15 $39,001 - $51,633	10,026 New	10,026 $40,000

Others Institutions Holding ADMA

# of Institutions

320

Shares Held

185M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.66B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Account

Oppenheimer & CO Inc Adma Biologics, Inc. Transaction History